Editorial Introductions : Current Opinion in Oncology

Secondary Logo

Journal Logo


Editorial Introductions

Editor(s): Klastersky, Jean; Jungels, Christiane; Pirker, Robert; Zhou, Caicun

Current Opinion in Oncology 35(1):p v-vi, January 2023. | DOI: 10.1097/CCO.0000000000000920
  • Free

Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue.


Jean Klastersky

Jean Klastersky

Professor Klastersky was Head of the Department of Medicine at the Institut Jules Bordet in Brussels, Belgium, and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles, Belgium, from 1977. He retired from these positions in 2005. Currently, he is the coordinator of the “Programme des Soins Oncologiques” for the Public Hospitals in Brussels and consultant in medical oncology at the Institut Jules Bordet, Belgium.

Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968, he was Chief-Resident at Boston City Hospital, USA, and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory Harvard Medical School, USA. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977.

Professor Klastersky was a founder member of the European Lung Cancer Working Party and was President from 1978 until 2003. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000.

He has been Visiting Professor of Medical Oncology at the Charles University in Prague, Czech Republic, since 1994.

Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium and various other international and national medical and/or oncological societies.

Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books.

He is the Editor of Current Opinion in Oncology.


Christiane Jungels

Christiane Jungels

Christiane Jungels, MD, is a Medical Oncologist at the Jules Bordet Institute in Brussels, Belgium. A Luxembourgish citizen, she came to Belgium in 2004 for Medical School at the Université Libre de Bruxelles (ULB), where she graduated as a Medical Doctor in 2010. She first trained in internal medicine, and later did her training in medical oncology at the Jules Bordet Institute, and graduated as a medical oncologist in 2016. She has been working in the Institute as a specialist since the end of 2016, with a primary interest the management of rare tumors, including sarcomas and endocrine tumors. Besides coordinating projects focusing on rare tumors, her main activity is clinical research, especially early drug development for patients with solid tumors with a special commitment to rare tumors. She is local Principal Investigator for several phase 1 trials and co-investigator in many phase 1 to 3 studies.

She is member of the Belgian Society for Medical Oncology (BSMO) and the European Society for Medical Oncology (ESMO).

Robert Pirker

Robert Pirker

Robert Pirker obtained a master's degree in biochemistry in 1978 and his medical degree in 1979 from the University of Vienna, Austria. He has been working at the Medical Faculty of the University of Vienna and the Medical University of Vienna. He obtained licences for Internal Medicine, Hemato-Oncology and Nuclear Medicine. He also worked as NIH Visiting Fellow at the Laboratory of Molecular Biology (Chief: Dr Ira Pastan), National Cancer Institute, Bethesda, MD, USA (1983–86).

His research interests are chemotherapy and targeted therapy of lung cancer, drug resistance mechanisms of cancer, predictive biomarkers, and management of chemotherapy-induced anaemia. He has published more than 220 articles, reviews or book chapters. According to Google Scholar (October 10, 2022), he has 25968 citations and an h-index of 64. He was an ESMO Faculty Member on Chest Tumors (2006–2011), a member including chair of the Educational Committee of IASLC (2004–2011; chair 2006–2009) and a member of the IASLC Board of Directors (2015–2019). He is on the Editorial Board of Lung Cancer and of Translational Lung Cancer Research. He is section editor for lung and mediastinum of Current Opinion in Oncology.

He was Congress President of the several Central European Lung Cancer Conferences, Chair of the Scientific Committee of the European Multidisciplinary Conference on Thoracic Oncology in 2009, Conference President of the IASLC 17th World Conference on Lung Cancer and Honorary Chair of the IASLC 2022 World Conference on Lung Cancer. He was a Co-Organizer of the 10th Chinese-German Lung Cancer Forum in Vienna in 2018. Since his retirement from the General Hospital of Vienna in October 2018, he has been working in private practice in Vienna and teaching Medical Oncology at the Medical University of Vienna, Austria. As current President of the Central European Lung Cancer Association he focusses on improving care of patients with lung cancer in Central European countries through education and co-operation.

Caicun Zhou

Caicun Zhou

Prof. Zhou studied medicine at Nantong Medical College and got Master of Medicine degree at Bengbu Medical College and PhD at China Medical University in China. He worked at Affiliated Hospital of Bengbu Medical College until 1998. In 1998, Prof. Zhou moved to Shanghai and got a position as professor and director in the Department of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University, China.

He has more than 30 years of experience in clinical oncology with his main research interests focusing on early detection, molecular targeted therapy, and immunotherapy in lung cancer. He has led or been involved in many multicenter clinical studies, including OPTIMAL, ALESIA, BEYOND, CAMEL, RATIONAL 303, CAEML-sq, etc.

Prof. Zhou has published over 200 articles in the peer-review journals, including the Lancet Oncology, Lancet Respiratory Medicine and Journal of Clinical Oncology. He is also involved in several professional societies, including BOD of IASLC, associate editor of IASLC Newsletter, chairmen of the NSCLC expert society in Chinese Society of Clinical Oncology (CSCO) and chairman of Thoracic Oncology Society in CPAM.

In addition, he is the Editor-in-Chief of the Translation Lung Cancer Research, the Associate Editor of the Lung Cancer and serves on the Editorial Board of several other major oncology journals.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.